Modified peptides as therapeutic agents
AssigneeAmgen Inc.
InventorsUlrich Feige, Chuan-Fa Liu
Life of this patent
Estimating the term…
Abstract
The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
Claims10
A composition of matter of the formula
- (X1)a-F1-(X2 )b
- and multimers thereof, wherein:
- F1 is an Fc domain;
- X1 and X2 are each independently selected from -(L1)c-P1, -(L1)cP1-(L2)dP2, -(L1)c-P1-(L2)d-P2-(L3)e-P3, and -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
- P1, P2, P3 , and P4 are each independently randomized IL-1 antagonist peptide sequences;
- L1, L2, L3, and L4 are each independently linkers;
- and
- a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein “peptide” refers to molecules of 2 to 40 amino acids and wherein neither X1 nor X2 is a native protein.
Dependencies are inferred from the claim text.